Reuters logo
BRIEF-EMA recommends approving new Eli Lilly rheumatoid arthritis drug
December 16, 2016 / 12:43 PM / a year ago

BRIEF-EMA recommends approving new Eli Lilly rheumatoid arthritis drug

Dec 16 (Reuters) - European Medicines Agency

* Recommends approval of Eli Lilly’s baricitinib for the treatment of moderate to severe active rheumatoid arthritis

* Recommended conditional marketing approval for Alecensa for the treatment of ALK-positive advanced NSCLC previously treated with crizotinib Source text: (bit.ly/2gSm1R3) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below